PRECLINICAL ASSESSMENT OF DUAL ERBB1/ERBB2 TARGETING AS A POTENTIAL ADJUVANT MOLECULAR THERAPY FOR INTRAHEPATIC CHOLANGIOCARCINOMA

被引：0
|
作者：
Sirica, Alphonse E. [1 ]
Zhang, Zichen [1 ]
Campbell, Deanna J. [1 ]
机构：
[1] Virginia Commonwealth Univ, Sch Med, Richmond, VA USA
来源：
HEPATOLOGY | 2008年 / 48卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
221
引用
收藏
页码：408A / 408A
页数：1
相关论文
共 50 条
  • [31] Androgens regulation of the ERBB1 and ERBB2 oncogene expression in human prostate cancer cells.
    Pignon, Jean-Christophe
    Delacroix, Laurence
    Waltregny, David
    Winkler, Rosita
    ACTA CLINICA BELGICA, 2006, 61 (02): : 95 - 95
  • [32] Combined antitumor efficacies of TAK-285, a novel ErbB1/ErbB2 dual kinase inhibitor, with other anticancer drugs
    Tamura, T.
    Takagi, S.
    Horikoshi, K.
    Yusa, T.
    Koyama, M.
    Tojo, H.
    Ohta, Y.
    EJC SUPPLEMENTS, 2008, 6 (12): : 100 - 101
  • [33] Cancer: A limited role for dual EGFR and ErbB2 inhibition in cholangiocarcinoma?
    Nanda S.
    Nature Reviews Gastroenterology & Hepatology, 2010, 7 (11) : 591 - 591
  • [34] Gw572016, a dual tyrosine kinase inhibitor, blocks activation of Erbb1 and Erbb2 in a bladder cancer cell line
    McHugh, LA
    Griffiths, TR
    Colquhoun, AJ
    Kriajevska, M
    Mellon, JK
    JOURNAL OF UROLOGY, 2004, 171 (04): : 188 - 188
  • [35] Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts
    Mellinghoff, IK
    Tran, C
    Sawyers, CL
    CANCER RESEARCH, 2002, 62 (18) : 5254 - 5259
  • [36] Quantification of Differential ErbB1 and ErbB2 Cell Surface Expression and Spatial Nanoclustering through Plasmon Coupling
    Wang, Jing
    Yu, Xinwei
    Boriskina, Svetlana V.
    Reinhard, Bjoern M.
    NANO LETTERS, 2012, 12 (06) : 3231 - 3237
  • [37] Molecular interactions of ERBB2 -: Implications for cancer therapy
    Vereb, G
    Nagy, P
    Zsebik, B
    Friedlander, E
    Isola, J
    Jovin, TM
    Park, JW
    Szöllosi, J
    CYTOMETRY PART A, 2004, 59A (01): : 93 - 93
  • [38] AZD8931, an equipotent, reversible inhibitor of erbB1, erbB2 and erbB3 receptor signalling: characterisation of pharmacological profile
    Klinowska, T.
    Hickinson, M.
    Speake, G.
    Marshall, G.
    Beck, S.
    Smith, P.
    Vincent, J.
    Anderton, J.
    Gray, N.
    Ogilvie, D.
    EJC SUPPLEMENTS, 2009, 7 (02): : 127 - 128
  • [39] Evaluation of AZD8931, an Equipotent Inhibitor of erbB1, erbB2, and erbB3 Receptor Signaling, on Ligand Stimulated Breast Cancer Cell Lines with Differing Levels of erbB2 Expression
    Marshall, G.
    Klinowska, T. C. M.
    Mills, E. A.
    Ogilvie, D.
    Hickinson, D. M.
    Speake, G.
    CANCER RESEARCH, 2009, 69 (24) : 784S - 785S
  • [40] Determining molecular phenotypes of metastatic breast cancer that respond to the small molecule inhibitor of ErbB1 and ErbB2, lapatinib (GW572016)
    Blackwell, KL
    Kaplan, EH
    Franco, SX
    Marcom, PK
    Maleski, JE
    Spector, NL
    Stocum, MT
    Sorensen, MJ
    Berger, MS
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S30 - S30
12345